<< Debate focuses on cost for coverage mandates | Parents' insurance status affects their children's health care--even when the children are insured >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Dansk | Nederlands | Ελληνικά | עִבְרִית | Русский | Svenska | Polski

HPN-100 drug receives orphan product designation

Published on September 18, 2009 at 2:12 AM · No Comments

Hyperion Therapeutics, Inc. today announced that its investigational product HPN-100 (glycerol phenylbutyrate) has received orphan product designation from the U.S. Food and Drug Administration for intermittent or chronic treatment of patients with cirrhosis and any grade of hepatic encephalopathy.

The Company is planning to initiate a phase II clinical program in this indication later this year.

http://www.hyperiontx.com/

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading